About Hidragon Capital
Hidragon Capital is a venture capital firm founded in 2011. It is primarily based out of Shanghai, China. As of Oct 2021, Hidragon Capital has invested in 3 companies. It primarily invests in Series C round in China based startups. Its investments are spread across Life Sciences sector. Most recently it participated in the $***** Series C round of Baicare A lot of funds co-invest with Hidragon Capital, with names like CMB International Capital sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series C & Series D
Portfolio Soonicorns
Hidragon Capital's List of All Investments
Hidragon Capital has a portfolio of 3 companies. Their most notable investments are in ET Healthcare and Baicare.Their portfolio spans across and China. They have invested in Life Sciences, across Series C, Series D stages. Here is the list of all investments by Hidragon Capital:EpimAb Biotherapeutics is a privately owned R&D company focussed on developing bispecific antibody therapeutics with its proprietary technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin). The technology re-arranges the DNA sequences of two MAbs into three constructs and co-expressing them in mammalian cells, it generates bi-specific FIT-Igs that fully retain the biological function of their parental MAbs.It is currently creating a pipeline of its own bispecific antibody therapeutics focused around immuno-oncology. It has collaboration with Innovent Biologics to develop Multi-Target Bispecific Antibody. Their lead candidate is EMB-01 a bispecific antibody based on EpimAb’s proprietary platform FIT-Ig, which according to company claims has shown promising results in multiple preclinical cancer models.
Key facts about EpimAb Biotherapeutics
- Founded Year: 2015
- Location: Shanghai (China)
- Stage: Series C
- Total Funding till date: $219M
- Investors: Mirae Asset, Cormorant Asset Management and 14 Others
- Latest Funding Round: Series C, Mar 22, 2021, $*****
- Highlight: Editors' Pick
Provider of an electrochemiluminescence analyzer. The analyzer works with a variety of sample types, including whole blood, plasma, serum. The analyzer runs on a single reagent and has a micro-blood mode for pediatric test troubles. Their systems are based on patented Cyclic Enhanced Fluorescence Assay (CEFA) technology and automated Pylon technology.
Key facts about ET Healthcare
- Founded Year: 2008
- Location: Shanghai (China)
- Stage: Series D
- Total Funding till date: $15.5M
- Employee Count: 24 as on May 31, 2026
- Investors: Legend Capital, Kaiser Permanente and 9 Others
- Latest Funding Round: Series D, May 10, 2021, $*****
- Highlight: Editors' Pick
3. Baicare
Baicare engages in development and manufacturing of instruments and reagents for the life science community. The product portfolio of the company includes microfluidic fluorescent chip, series of QPCR equipment, RT PCR reagents, and other molecular biology reagents.
Key facts about Baicare
- Founded Year: 2016
- Location: Beijing (China)
- Stage: Series C
- Total Funding till date: $6.18M
- Employee Count: 7 as on May 31, 2026
- Investors: LYFE Capital, K2VC and 2 Others
- Latest Funding Round: Series C, Mar 18, 2022, $*****
Hidragon Capital's Year-on-Year Investment Trends
Hidragon Capital has invested in 3 companies over the last 5 years, with an average of 0 new investment annually in the last 5 years. Its most recent first time investment was in Baicare.Hidragon Capital's Investments by Stage
Hidragon Capital has made 2 investments in Series C stage with an average round size of $120M and 1 investment in Series D stage with an average round size of $15.5M.Stage of entry | No. of Investments |
|---|---|
Series C | 2 |
Series D | 1 |
Note: We have considered here, only first round of investments
Hidragon Capital's Investments by Sector
Hidragon Capital has a portfolio focused on Life Sciences. Notably, it has invested in 3 Tech companies, 2 Enterprise (B2B) companies, 1 Software company and 1 company focusing on Tech hardware.Hidragon Capital's Investments by Geography
Hidragon Capital has made most investments in China (3).Hidragon Capital's recent investments
Hidragon Capital has not made any investment in 2026 so far.Here are the most recent investments by Hidragon Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 26, 2021 | China | Series C | 5324 | - | |
May 10, 2021 | China | Series D | 9154 | ||
Mar 22, 2021 | China | Series C | 8798 |
Co-investors of Hidragon Capital
Over the past 5 years, 27 investors have co-invested in Hidragon Capital's portfolio companies. This includes funds and angels.
- Invested before Hidragon Capital: SDIC Innovation, Sherpa Venture Capital and 11 others have invested in rounds before Hidragon Capital. There is 1 company where SDIC Innovation has invested before Hidragon Capital and 1 company where Sherpa Venture Capital has invested before Hidragon Capital.
- Top Co-investors of Hidragon Capital: 14 investors entered a company along with Hidragon Capital. These include investors like CMB International Capital (1 company).
Recent News related to Hidragon Capital
•
China medical tech supplier AMS raises $100mAsian Venture Capital Journal•May 12, 2021•Access Medical Systems, Sequoia Capital, GL Ventures, Kaiser Permanente and 5 others
•
•
EpimAb reels in $120M to propel 3 clinical-stage bispecifics, including dual checkpoint inhibitorFierce Biotech•Mar 22, 2021•EpimAb Biotherapeutics, Cormorant Asset Management, Yanchuang Capital, ShangBay Capital and 7 others
